AngioDynamics (ANGO) Reports In-Line Q2 EPS; Trims FY16 Outlook

AngioDynamics (NASDAQ: ANGO) reported Q2 EPS of $0.14, in-line with the analyst estimate of $0.14. Revenue for the quarter came in at $89.2 million versus the consensus estimate of $88.67 million.

GUIDANCE:

AngioDynamics sees Q3 2016 EPS of $0.10-$0.14, versus the consensus of $0.17. AngioDynamics sees Q3 2016 revenue of $84-87 million, versus the consensus of $91.7 million.

AngioDynamics sees FY2016 EPS of $0.59-$0.63, versus the consensus of $0.62. AngioDynamics sees FY2016 revenue of $353-359 million, versus the consensus of $362.9 million.

For earnings history and earnings-related data on AngioDynamics (ANGO) click here.

You May Also Be Interested In

• DocGo (DCGO) Misses Q2 EPS by 6c; Offers Guidance
• Smith-Midland Corporation (SMID) Tops Q2 EPS by 26c
• BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown